synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-29. Anything still debated is marked as such rather than presented as settled.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Willis, who predicted them using a dynamic homogenization method. Much of the recent interest in Willis couplings has been driven by their local form (the Milton–Briane–Willis equations). By extending Willis's homogenization method, Pernas-Salomón and Shmuel were the first to show that piezoelectric composites exhibit an effective coupling between linear momentum and the electric field, which they termed electro-momentum coupling. Electro-momentum coupling provides a mechanism for wave manipulation similar to Willis coupling, with the added benefit of electrical tunability.
== Clinical relevance == In normal dopamine and serotonin (5-HT) neurotransmitter synthesis, AADC is not the rate-limiting step in either reaction. However, AADC becomes the rate-limiting step of dopamine synthesis in patients treated with L-DOPA (such as in Parkinson's disease), and the rate-limiting step of serotonin synthesis in people treated with 5-HTP (such as in mild depression or dysthymia). AADC is inhibited by carbidopa outside of the blood brain barrier to inhibit the premature conversion of L-DOPA to dopamine in the treatment of Parkinson's. In humans, AADC is also the rate-limiting enzyme in the formation of trace amines. Aromatic L-amino acid decarboxylase deficiency is associated with various symptoms as severe developmental delay, oculogyric crises and autonomic dysfunction. The molecular and clinical spectrum of AAAC deficiency is heterogeneous. The first case of AADC deficiency was described in twin brothers 1990. Patients can be treated with dopamine agonists, MAO inhibitors, and pyridoxine (vitamin B6). Clinical phenotype and response to treatment is variable and the long-term and functional outcome is unknown. To provide a basis for improving the understanding of the epidemiology, genotype–phenotype correlation and outcome of these diseases their impact on the quality of life of patients, and for evaluating diagnostic and therapeutic strategies a patient registry was established by the noncommercial International Working Group on Neurotransmitter Related Disorders (iNTD).
== Classical solutions for non-adhesive elastic contact == The theory of contact between elastic bodies can be used to find contact areas and indentation depths for simple geometries. Some commonly used solutions are listed below. The theory used to compute these solutions is discussed later in the article. Solutions for multitude of other technically relevant shapes, e.g. the truncated cone, the worn sphere, rough profiles, hollow cylinders, etc. can be found in
Sources: en.wikipedia.org
The rate of proteolysis may also depend on the physiological state of the organism, such as its hormonal state as well as nutritional status. In time of starvation, the rate of protein degradation increases.
Kennedy left the Foster administration when he was elected Louisiana State Treasurer in 1999, having unseated incumbent Ken Duncan with 55.6% of the vote, or 621,796 votes, to Duncan's 44.4%, or 497,319 votes. Kennedy was reelected treasurer without opposition in 2003, 2007 and 2011. In 2015, he defeated his sole challenger with 80% of the vote.
=== Establishment === The British South Africa Police's Special Branch began pseudo operations to collect intelligence in 1966. The Rhodesian Army took part in a joint trial using these tactics with the British South Africa Police and Special Branch that year, but it was not successful for at that stage the black population was largely indifferent to the insurgents and so not able to provide intelligence on them. The ZANLA began to gain control over north-eastern Rhodesia from 1971, and considerably strengthened its influence over the population in the region over the next year. This led to the networks of informers who had provided information to the Rhodesian Government ceasing to do so, which made it difficult for the security forces to locate and counter the insurgents. In response, Special Branch began to establish pseudo teams in January 1973. The Rhodesian Army also formed two such teams in February; these comprised members of C Squadron 22 (Rhodesian) SAS, black soldiers from the Rhodesian African Rifles and former insurgents. These teams enjoyed success, leading to a decision to expand pseudo operations. Major Ronald Francis Reid-Daly was selected to command the unit that became the Selous Scouts in November 1973. He was personally selected for this role by Lieutenant General Peter Walls, the head of the Rhodesian Army. An initial group of 25 personnel were selected and trained at Makuti near Lake Kariba. The first troop completed training and began operations in January 1974, followed by two other troops in February and March that year.
Sources: en.wikipedia.org
=== East Asia === Some historians believe that saffron came to China with Mongol invaders from Persia. In the field of traditional Chinese medicine, it was first mentioned in the Yinshan zhengyao as an ingredient to treat "internal blazing of heart fire". Shennong Bencaojing, a pharmacopoeia written around 300–200 BC and traditionally credited to the legendary Yan Emperor and the deity Shennong, also mentions saffron among 252 plant-based medical treatments for various disorders. Nevertheless, around the 3rd century AD, the Chinese were referring to it as having a Kashmiri provenance through the Silk Road. According to the herbalist Wan Zhen, "the habitat of saffron is in Kashmir, where people grow it principally to offer it to the Buddha". Wan also reflected on how it was used in his time: "The flower withers after a few days, and then the saffron is obtained. It is valued for its uniform yellow colour. It can be used to aromatise wine." Saffron is a less common food colouring ingredient in local Chinese cuisines than safflower. Since the 1970s, Chinese saffron farming has begun in Maqiao, Shanghai's Minhang district, as well as in Changji, Xinjiang.
=== 19th century: Early history === Dairy Farm Company Ltd was set up in 1886 by Sir Patrick Manson, a Scottish surgeon, along with Sir Paul Chater, Mr Phineas Ryrie, Mr Granville Sharp, Mr WH Ray and Mr JB Coughtry, five other prominent Hong Kong businessmen. The company was created with three founding objectives: to improve the health of Hong Kong people by providing them with non-contaminated cows' milk, to breed a herd of imported dairy cattle locally to decrease the price of milk by half, and to realise profit for its shareholders. Manson purchased 80 Friesian cows from Scotland and a plot of land for his farm in Pok Fu Lam. In 1890, Dairy Farm built a low-rise brick and stucco building on Lower Albert Road in Central for use as a cold storage warehouse. This warehouse was later renovated and expanded in 1913 to include a dairy shop, a room for meat smoking, a cold storage room for winter clothes and residency for its manager. The building later evolved into the company headquarters until the company moved in the 1970s. The abandoned building was acquired by the Hong Kong Fringe Club, a non-profit-making arts organisation in 1984, and has been carefully restored. This distinctive 19th century building, known as the Old Dairy Farm Depot, is a well-known landmark in Central providing a wide variety of cultural activities and performances.
Aldehyde tags were first inserted into the modified sulfatase motif peptide for proteins of interest in 2007. Since then, similar usage of aldehydes and ketones as chemical reporters in bioorthogonal applications has been demonstrated in self-assembly of cell-lysing drugs, the targeting of proteins, as well as glycans and the preparation of heterobifunctional fusion proteins.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.